Artiva Biotherapeutics (ARTV) Net Cash Flow (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Net Cash Flow data on file, last reported at -$5.7 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$5.7 million, up 40.34% year-over-year; the trailing twelve-month figure through Mar 2026 was -$9.5 million (up 40.58% YoY), and the FY2025 annual result was -$13.4 million, down 0.84% from the prior year.
• Net Cash Flow declined to -$5.7 million in Q1 2026 per ARTV's latest filing, from $1.1 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $21.6 million in Q3 2024 and troughed at -$15.6 million in Q4 2024.
• A 4-year average of -$2.8 million and a median of -$5.3 million in 2024 frame the typical range for Net Cash Flow.
• On a YoY basis, Net Cash Flow climbed as much as 107.31% in 2025 and fell as far as 113.68% in 2025.
• A 4-year view of Net Cash Flow shows it stood at -$12.4 million in 2023, then dropped by 26.37% to -$15.6 million in 2024, then jumped by 107.31% to $1.1 million in 2025, then sank by 602.27% to -$5.7 million in 2026.
• Business Quant data shows ARTV's Net Cash Flow at -$5.7 million in Q1 2026, $1.1 million in Q4 2025, and -$3.0 million in Q3 2025.